ClinicalTrials.gg
CompletedNCT06836128PCOSUpdated Oct 21, 2026

The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients

A Phase 3 interventional study of N-acetyl cysteine and Metfomin in Polycystic Ovary Syndrome, sponsored by Cairo University. Completed at 1 site in Egypt. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Cairo University · Phase 3, Interventional, and Treatment

How we know

Updated Oct 21, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Polycystic Ovary Syndrome by Cairo University — 10 open to participants now, 10 under way, none of them phase 3. Polycystic Ovary Syndrome · Cairo University.

Enrollment
4th of 26
102 · median 55
Started
2025
with 4 others
Phase 3
2 of 34
none open now
Registered
26th of 34
by date

Among the 34 studies in Polycystic Ovary Syndrome by Cairo University, this one is the 4th largest by enrollment of the 26 interventional ones that give a count, is one of 5 that started in 2025, is one of 2 in phase 3, and was the 26th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

10 of the 34 studies in Polycystic Ovary Syndrome by Cairo University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 20 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Polycystic Ovary Syndrome by Cairo University, or all of them as a file.
02

Study summary

The study aims to evaluate the effects of combination of metformin with NAC in PCOS on biochemical and hormonal parameters.

Read the detailed description

Polycystic ovarian syndrome (PCOS) is one of the prevalent endocrine illnesses that affects women in industrialized and developing nations, with a prevalence that ranges from 8% to 13%. The most widely accepted criteria for diagnosing polycystic ovary syndrome (PCOS) are the Rotterdam criteria established in 20032. According to these criteria, a diagnosis is made if a patient meets at least two of the following three criteria:

The Rotterdam criteria

Polycystic ovarian syndrome is diagnosed when 2 out of 3 criteria are met:

  1. Oligo-or/and anovulation
  2. Clinical hyperandrogenism (acne, hirsutism, alopecia) or biochemical hyperandrogenism.
  3. Polycystic ovarian morphology on transvaginal ultrasonography or high antimullerian hormone.

And exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome).

The 2023 International Evidence-based Guideline for the Assessment and Management of PCOS has built on the Rotterdam criteria by emphasizing more comprehensive assessments.

These updates highlight the need to consider a broader range of phenotypes, assess metabolic risks, and prioritize patient-centered, individualized care.

Algorithm: Screening and diagnostic assessment

Step 1:

Irregular Menstrual Cycles + Clinical Hyperandrogenism

  • Exclude other causes* = diagnosis.

Step 2:

Irregular Menstrual Cycles Without Clinical Hyperandrogenism • Test for biochemical hyperandrogenism and exclude other causes* = Diagnosis

Step 3:

If Only Irregular Cycles or Only Hyperandrogenism

  1. Adolescents: Ultrasound or AMH is not indicated = considered at risk of PCOS and reassessed later
  2. Adults: Ultrasound for Polycystic Ovarian morphology (PCOM)* OR Anti-Mullerian Hormone (AMH) level, if positive (exclude other causes) * = diagnosis

    • Exclusion of Other Causes = TSH, prolactin, FSH or, if clinically indicated, exclude other causes (e.g. Cushing's syndrome, adrenal tumors, etc.) Irregular menstrual cycles 1 to \< 3 years post-menarche: Cycle length is either less than 21 days or more than 45 days.

> 3 years post-menarche until perimenopause: Cycle length is either less than 21 days, more than 35 days, or fewer than 8 cycles per year.

> 1-year post-menarche: Any cycle lasting more than 90 days. Primary amenorrhea: no menstruation by age 15 or more than 3 years after the onset of breast development (thelarche).

Biochemical hyperandrogenism Elevated total or free testosterone, or calculated indices of free testosterone Clinical hyperandrogenism Comprehensive history and physical examination are needed. Adults: acne, female pattern hair loss, and hirsutism. Adolescents: severe acne and hirsutism.

Note the negative psychosocial impact of clinical hyperandrogenism. Standardized visual scales are preferred, including the modified Ferriman Gallway score (mFG), a score of ≥ 4-6 = hirsutism.

Ultrasound and polycystic ovary morphology (PCOM) and anti-mullerian hormone (AMH) Using ultrasound transducers with a frequency bandwidth including 8 MHz, the PCOM threshold is a follicle number per ovary of ≥ 20 and/or an ovarian volume ≥ 10 ml on either ovary, avoiding corpora lutea, cysts or dominant follicles.

Either serum AMH OR ultrasound may be used but not both to avoid overdiagnosis Serum AMH could be used for defining PCOM in adults as an alternative to pelvic or abdominal ultrasound.

People with PCOS often experience various metabolic and reproductive outcomes such as obesity, insulin resistance (IR), oxidative stress (OS), hirsutism, acne, irregular menstruation, and infertility, as well as long-term consequences including cancer and cardiovascular illnesses.

The cause of PCOS is still unknown, despite evidence indicating the pathophysiology of the condition is primarily driven by the production of high quantities of androgen and IR. Additionally, research showed that OS is linked to IR, hyperinsulinemia, hyperandrogenism, persistent inflammatory conditions, abnormalities in fat and carbohydrate metabolism, ovarian dysfunction, and unfavorable pregnancy outcomes. Consequently, antioxidant therapy might be useful in the management of PCOS. Patients with PCOS frequently seek treatment for a variety of symptoms, including menstrual irregularities, heavy menstrual bleeding, acne, hirsutism, and weight management challenges.

The management of PCOS is typically tailored to address these specific symptoms, with a range of therapeutic options available depending on the patient's presentation. Menstrual irregularity and heavy bleeding in patients with PCOS can be managed through lifestyle interventions, such as diet and exercise aimed at achieving a weight reduction of 5%-10%8, or by using combined hormonal contraceptives. These may include oral norethindrone acetate (5 mg daily for 7 days every 30-90 days, or 5 mg daily for 3 weeks on and 1 week off), ethinyl estradiol (20-35 mcg of ethinyl estradiol in combination with a progestin), or oral drospirenone (4 mg for 24 days, followed by 4 days of placebo). In cases where hormonal contraceptives are not suitable or effective, metformin (1500-2000 mg daily in divided doses, starting at 500 mg and increasing by 500 mg every 1-2 weeks) may be considered. Inositol supplementation, commonly administered as 4 g of myo-inositol daily, is another option that has been shown to improve menstrual regularity, metabolic disturbances, and reducing weight in patients with PCOS.

For managing acne, hirsutism, or alopecia, first-line treatments include combined hormonal contraceptives to address androgenic symptoms. In addition, topical treatments for hirsutism, such as 13% eflornithine, can help reduce unwanted facial hair. Minoxidil (2% solution, applied twice daily) is commonly used for the treatment of alopecia. Topical or oral acne treatments should follow general dermatological guidelines, depending on the severity of the condition.

Overweight or obesity is commonly addressed through lifestyle interventions. Metformin (1500-2000 mg daily in divided doses, with gradual titration starting at 500 mg) can be used to improve insulin sensitivity and aid in weight management.

For ovulation induction, letrozole (2.5 mg-7.5 mg for 5 days) is considered a first-line treatment for ovulation induction in many guidelines. To confirm successful ovulation, it is recommended to measure serum progesterone levels approximately 3 weeks after initiating letrozole. Metformin (1500-2000 mg daily) can also be used to enhance ovulatory function. Clomiphene is also used to induce ovulation, starting at 50 mg daily for 5 days from days 2-5 of the cycle. If ineffective, the dose may be increased to 100 mg or 150 mg in subsequent cycles for up to 6 cycles.

N-Acetyl Cysteine (NAC) has antioxidant properties and is essential for the body's production of glutathione, and both glutathione and NAC are potent antioxidants. By promoting the synthesis of glutathione synthetase hormone (GSH), NAC helps inhibit OS, preventing hyperinsulinemia-induced IR and protecting insulin receptors from oxidative damage. NAC likely enhances insulin receptor activity, leading to increased glucose consumption, which indicates improved insulin sensitivity. IR, dyslipidemia, and hyperhomocysteinemia are risk factors for ischemic heart disease in women with PCOS. NAC has been utilized as a therapeutic agent to improve homocysteine levels and lipid profiles, which in turn have been shown to affect insulin receptor activity. As a result, the primary cause of PCOS was alleviated and insulin levels fell. The antioxidant properties of NAC have been utilized in multiple clinical trials conducted on infertile PCOS females to increase oocyte quality and ovulation rate.

In this study, the investigators will evaluate and compare the efficacy of metformin and NAC combination versus metformin alone on clinical, metabolic, hormonal, and biochemical aspects in patients with PCOS.

03

Conditions studied

  • Polycystic Ovary Syndrome

Keywords

  • PCOS
  • NAC
  • metformin
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female aged 20 to 45 years old.
  2. Confirmed diagnosis with PCOS according to the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS.
  3. Ability to give .

Exclusion criteria

Exclusion Criteria:

  1. to either metformin or NAC.
  2. Consumption of medications affecting carbohydrate metabolism, such as insulin, sulfonylureas, and taking hormonal analogues two months prior to enrollment.
  3. Hyperprolactinemia, defined as a prolactin level above laboratory reference range.
  4. Diabetes mellitus.
  5. Thyroid dysfunction, subjects with elevated or low TSH level.
  6. Renal impairment where (CrCl) less than 30 ml/min.
  7. Severe hepatic impairment, defined as significant biochemical abnormalities, including hypoalbuminemia and abnormal serum concentration (2-3 times the ), of at least two of the following liver function markers: total , (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or gamma-glutamyl transferase (GGT).
  8. Active alcohol abuse.
  9. History of lactic acidosis during metformin therapy.
  10. Active peptic ulcer.
  11. Congenital adrenal hyperplasia.
  12. Cushing's syndrome.
  13. Androgen secreting neoplasia.
  14. Patients who were using spironolactone, other anti-androgens, or any form of hormone therapy for the treatment of hirsutism at least 3 months before enrollment in the study.
  15. Decompensated heart failure.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Group-MN

    Group-MN, constituting 51 cases, will receive N-acetyl cysteine and metformin (600 mg three times daily of acetyl cysteine and 500 mg once daily for one week, then 500 mg twice daily for one week, and 500 mg three times daily thereafter of metformin)

    Drug: N-acetyl cysteine · Drug: Metfomin

  • Experimental
    Group-M

    Group-M, constituting 51 cases, will receive treatment with metformin (starting with 500 mg once daily for one week, then 500 mg twice daily for one week, and 500 mg three times daily thereafter)

    Drug: Metfomin

Interventions

  • DrugAcetylcysteineStudies of AcetylcysteineAcetylcysteine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    N-Acetyl Cysteine (NAC) has antioxidant properties and is essential for the body's production of glutathione, and both glutathione and NAC are potent antioxidants.

    Also known as: NAC

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    metformin is commonly used for managing polycystic ovary syndrome (PCOS) due to its benefits in addressing several underlying features of the condition. While it is not officially approved by regulatory agencies like the FDA for PCOS, it is widely recognized and recommended in clinical practice guidelines as an off-label treatment for PCOS, particularly in women with insulin resistance and metabolic dysfunction.

06

What researchers measure

Primary outcomes

  1. Primary outcome will be change in LH/FSH levels.

    change in LH/FSH ratio

    Time frame: 3 months

Secondary outcomes

  1. improvement in hormonal levels in patients with PCOS

    Hormonal profile change in: Total testosterone levels (ng/dL) Free testosterone levels (ng/dL) Free testosterone to total testosterone (FT/TT) ratio, calculated from the measured values.

    Time frame: 3 months

  2. improvement in clinical features in patients with PCOS

    improvement in clinical features: Menstrual irregularities: improvement in oligomenorrhea or amenorrhea, assessed based on The 2023 International Evidence-based Guideline for the Assessment and Management of PCOS Hirsutism: Assessed using the modified Ferriman-Gallwey (mFG) score Acne: Evaluated using the Investigator Global Assessment (IGA) scale technique.

    Time frame: 3 months

  3. improvement in biochemical parameters in patients with PCOS

    biochemical parameters change in: Fasting insulin levels (µIU/mL). Fasting blood glucose (FBG) levels (mg/dL). Glucose/insulin ratio, calculated using fasting glucose and insulin levels. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated using the standard formula.

    Time frame: 3 months

  4. improvement in metabolic parameters in patients with PCOS

    weight in kilograms, height in meters Body mass index (BMI) (kg/m2), calculated as weight (kg) divided by height (m2).

    Time frame: 3 months

07

Study locations

1 site
  • Kasr El-Ainy hospital
    Cairo, Egypt
08

References and documents

Publications

  • Tiganis T. Reactive oxygen species and insulin resistance: the good, the bad and the ugly. Trends Pharmacol Sci. 2011 Feb;32(2):82-9. doi: 10.1016/j.tips.2010.11.006. Epub 2010 Dec 14. PubMed 21159388 ↗
  • Pei Y, Liu H, Yang Y, Yang Y, Jiao Y, Tay FR, Chen J. Biological Activities and Potential Oral Applications of N-Acetylcysteine: Progress and Prospects. Oxid Med Cell Longev. 2018 Apr 22;2018:2835787. doi: 10.1155/2018/2835787. eCollection 2018. PubMed 29849877 ↗
  • Yifu P. A review of antioxidant N-acetylcysteine in addressing polycystic ovary syndrome. Gynecol Endocrinol. 2024 Dec;40(1):2381498. doi: 10.1080/09513590.2024.2381498. Epub 2024 Jul 22. PubMed 39039898 ↗
  • Christ JP, Cedars MI. Current Guidelines for Diagnosing PCOS. Diagnostics (Basel). 2023 Mar 15;13(6):1113. doi: 10.3390/diagnostics13061113. PubMed 36980421 ↗
  • Gayatri K, Kumar JS, and Kumar BB. Metformin and N-acetyl cysteine in polycystic ovarian syndrome--a comparative study. Indian Journal of Clinical Medicine. 2023;15;24(18):14126. doi.org/10.1177/117739361000100002
  • Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation. 2004 Jan 27;109(3):369-74. doi: 10.1161/01.CIR.0000109492.65802.AD. Epub 2004 Jan 19. PubMed 14732754 ↗
  • Fulghesu AM, Ciampelli M, Muzj G, Belosi C, Selvaggi L, Ayala GF, Lanzone A. N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil Steril. 2002 Jun;77(6):1128-35. doi: 10.1016/s0015-0282(02)03133-3. PubMed 12057717 ↗
  • De Mattia G, Bravi MC, Laurenti O, Cassone-Faldetta M, Proietti A, De Luca O, Armiento A, Ferri C. Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes. Diabetologia. 1998 Nov;41(11):1392-6. doi: 10.1007/s001250051082. PubMed 9833950 ↗
  • Brown J, Farquhar C. Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome. Cochrane Database Syst Rev. 2016 Dec 15;12(12):CD002249. doi: 10.1002/14651858.CD002249.pub5. PubMed 27976369 ↗
  • Costello M, Garad R, Hart R, Homer H, Johnson L, Jordan C, Mocanu E, Qiao J, Rombauts L, Teede HJ, Vanky E, Venetis C, Ledger W. A Review of First Line Infertility Treatments and Supporting Evidence in Women with Polycystic Ovary Syndrome. Med Sci (Basel). 2019 Sep 10;7(9):95. doi: 10.3390/medsci7090095. PubMed 31510088 ↗
  • Martin KA, Anderson RR, Chang RJ, Ehrmann DA, Lobo RA, Murad MH, Pugeat MM, Rosenfield RL. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1233-1257. doi: 10.1210/jc.2018-00241. PubMed 29522147 ↗
  • Greff D, Juhasz AE, Vancsa S, Varadi A, Sipos Z, Szinte J, Park S, Hegyi P, Nyirady P, Acs N, Varbiro S, Horvath EM. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023 Jan 26;21(1):10. doi: 10.1186/s12958-023-01055-z. PubMed 36703143 ↗
  • Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018 Sep 1;33(9):1602-1618. doi: 10.1093/humrep/dey256. PubMed 30052961 ↗
  • Dason ES, Koshkina O, Chan C, Sobel M. Diagnosis and management of polycystic ovarian syndrome. CMAJ. 2024 Jan 28;196(3):E85-E94. doi: 10.1503/cmaj.231251. No abstract available. PubMed 38286488 ↗
  • Schuring AN, Schulte N, Sonntag B, Kiesel L. Androgens and insulin--two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome. Gynakol Geburtshilfliche Rundsch. 2008;48(1):9-15. doi: 10.1159/000111465. Epub 2008 Jan 17. PubMed 18209494 ↗
  • Zeber-Lubecka N, Ciebiera M, Hennig EE. Polycystic Ovary Syndrome and Oxidative Stress-From Bench to Bedside. Int J Mol Sci. 2023 Sep 15;24(18):14126. doi: 10.3390/ijms241814126. PubMed 37762427 ↗
  • International Evidence-Based Guideline for the Assessment. 2023, www.monash.edu/__data/assets/pdf_file/0003/3379521/Evidence-Based-Guidelines-2023.pdf.
  • Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 Jan;19(1):41-7. doi: 10.1093/humrep/deh098. PubMed 14688154 ↗
  • Skiba MA, Islam RM, Bell RJ, Davis SR. Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2018 Nov 1;24(6):694-709. doi: 10.1093/humupd/dmy022. PubMed 30059968 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Mar 2026, 12 months.

Of 26 non-industry phase 3 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's 12 months is below that.

Counting every sponsor, half of 26 studies reached it within 28 months; a quarter within 11 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Feb 2026 → Mar 2026 and completion May 2026 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2025
First posted
Feb 20, 2025
StartActual
Mar 1, 2025
Primary completionActual
Mar 30, 2026was Feb 2026
CompletionActual
Mar 30, 2026was May 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 21, 2026
Primary completion
Feb 1, 2026→Mar 30, 2026 (actual)
Oct 21, 2026
Study completion
May 1, 2026→Mar 30, 2026 (actual)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Recruiting→Completed
    Primary completion Feb 1, 2026→Mar 30, 2026 (now actual)
    Study completion May 1, 2026→Mar 30, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06836128
Lead sponsor
Cairo University
Responsible party
Marwa Rafat Talat (Demonstrator and Teaching assistant, Cairo University) — Principal investigator
First posted
Feb 20, 2025
Start date
Mar 1, 2025
Primary completion
Mar 30, 2026
Completion
Mar 30, 2026
Last update
Oct 21, 2026

Study contacts

Samar F Farid, PhD
study director · Professor and Head of Clinical Pharmacy Department, Faculty of Pharmacy, Cairo University
Eglal A Mostafa Bassiouny, PhD
study director · Lecturer of Clinical Pharmacy Faculty of Pharmacy, Cairo University
Amr Z Abdelhamid, PhD
study director · Obstetrics and Gynaecology Lecturer Kasr Al-Ainy School of Medicine, Cairo University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetylcysteine

Start the discussion